Accell Group NV (CE) (ACGPF) Quote

Much better sales team than ibat and smart enough to fill out paperwork for loans and grants. IBAT has no brines their biggest downfall.

You watch E3 will get grant soon. E3 will receive more than 2% royalties better play in the long run than ibat. Also E3 can sell the brines anytime

My thought on BLMZ

With BloomZ making strides in innovative projects and expanding into new markets, it seems well-positioned to reach the $35 million Nasdaq market cap requirement. The company’s recent developments have caught the attention of investors who are optimistic about its g

Ask yourself, why Delaware

Whinny R - you seem to be self aware- at least in admitting to being a no one.

All of which is generating how much in revenues?? Enough to pay for all the promotions?

Devin Nunes understands social media.

Not far fetched!!!

Good morning everyone! $ZHUD’sters!

Is that all you got....please put your pic up so we can see you huge nose...🤣🤣🤣

The $ASII pot is boiling $$$
$ASII had a great call with NASDAQ Nordic Specialist today!
HUGE UPDATE NEXT, we’re just getting started
#UPLIST #NORDIC
9:48 AM · Sep 19, 2024
·
2,308
Views

Can Adnexus do the blood pressure test results :)

Knos looks good isn’t it?

$AGBA GROUP UPDATE:
•AGBA's merger with Triller Corp. is on track to close

•Shareholder approval was granted for AGBA to be incorporated as a Delaware Corporation and domiciled in the U.S., operating under the name Triller Group Inc.

•All AGBA/Triller merger clos

Just finished off a Skyline chili cheese dog with onion and mustard at 8:20 am😃 GLTA!!

Excellent!!!! Call!!! v!!!!

Don't let him get to you he will go away as soon as he finds another stock to complain about.

TJ i have been in some cemeteries and they have been noisier than Jim

Quite Frankly i think i heard Frankenstein and Dracula in one graveyard talking about Jim and AFFU while the bats 🦇 where flying around

NotSure2,

Thanks for asking!

Yes! Absolutely! The benefits, both realized and potential for each patient, are notably high and significant for the most challenging cancers to treat and survive—newly diagnosed GBM (nGBM) and recurrent GBM (rGBM). The JAMA study highligh

I never said it wasn’t. You said you have never seen such a small float in trips…

Which is obviously very wrong. So I pointed you to one.

In at $7.00 Holding for $150.00

VKTX

$GNS is a NO 🧠’er buy and hold for a FAIR MARKET VALUE

$105m revenue 2024

Current Market Cap 19m

The revenue multiple, is a valuation metric used to estimate the value of a company based on its revenue.

In the education market, det

$GNS is a NO 🧠’er buy and hold for a FAIR MARKET VALUE

$105m revenue 2024

Current Market Cap 19m

The revenue multiple, is a valuation metric used to estimate the value of a company based on its revenue.

In the education market, det

newsday

$CVKD - Zacks initiating coverage of Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) with a $30.00 valuation. Cadrenal is a biopharmaceutical developing innovative therapies for life-threatening cardiovascular and renal diseases. https://scr.zacks.com/news/news-details/2024/CVKD-New-Blood-Thinner-Ready-f